de Jong S - Search Results

1

Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment.

Rosas-Plaza X, de Vries G, Meersma GJ, Suurmeijer AJH, Gietema JA, van Vugt MATM, de Jong S. Rosas-Plaza X, et al. Among authors: de vries g, de jong s. Mol Cancer Ther. 2020 Feb;19(2):590-601. doi: 10.1158/1535-7163.MCT-19-0449. Epub 2019 Nov 19. Mol Cancer Ther. 2020. PMID: 31744897

2

Effect of novobiocin on cisplatin cytotoxicity and DNA interstrand cross-link formation in a cisplatin-resistant, small-cell lung carcinoma cell line.

de Jong S, Timmer-Bosscha H, de Vries EG, Mulder NH. de Jong S, et al. Among authors: de vries eg. Int J Cancer. 1993 Jan 2;53(1):110-7. doi: 10.1002/ijc.2910530121. Int J Cancer. 1993. PMID: 8380054

3

Expression of proteins correlated with the unique cisplatin-sensitivity of testicular cancer.

de Graaf TW, de Jong S, de Vries EG, Mulder NH. de Graaf TW, et al. Among authors: de vries eg, de jong s. Anticancer Res. 1997 Jan-Feb;17(1A):369-75. Anticancer Res. 1997. PMID: 9066679

4

Telomerase in (pre)neoplastic cervical disease.

Wisman GB, De Jong S, Meersma GJ, Helder MN, Hollema H, de Vries EG, Keith WN, van der Zee AG. Wisman GB, et al. Among authors: de vries eg, de jong s. Hum Pathol. 2000 Oct;31(10):1304-12. doi: 10.1053/hupa.2000.19299. Hum Pathol. 2000. PMID: 11070123

5

Correspondence re: C. G. Ferreira et al., Apoptosis: target of cancer therapy. Clin. Cancer Res., 8: 2024-2034, 2002.

de Vries EG, de Hooge MN, Gietema JA, de Jong S. de Vries EG, et al. Among authors: de hooge mn, de jong s. Clin Cancer Res. 2003 Feb;9(2):912; author reply 913. Clin Cancer Res. 2003. PMID: 12576467 No abstract available.

6

Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line.

Spierings DC, de Vries EG, Vellenga E, de Jong S. Spierings DC, et al. Among authors: de vries eg, de jong s. Cell Death Differ. 2003 Jul;10(7):808-22. doi: 10.1038/sj.cdd.4401248. Cell Death Differ. 2003. PMID: 12815464

7

Modulation of death receptor pathways in oncology.

de Vries EG, Timmer T, Mulder NH, van Geelen CM, van der Graaf WT, Spierings DC, de Hooge MN, Gietema JA, de Jong S. de Vries EG, et al. Among authors: de hooge mn, de jong s. Drugs Today (Barc). 2003;39 Suppl C:95-109. Drugs Today (Barc). 2003. PMID: 14988748 Review.

8

Low p21Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis.

Spierings DC, de Vries EG, Stel AJ, te Rietstap N, Vellenga E, de Jong S. Spierings DC, et al. Among authors: de vries eg, de jong s. Oncogene. 2004 Jun 17;23(28):4862-72. doi: 10.1038/sj.onc.1207617. Oncogene. 2004. PMID: 15122333

9

Preclinical characterisation of 111In-DTPA-trastuzumab.

Lub-de Hooge MN, Kosterink JG, Perik PJ, Nijnuis H, Tran L, Bart J, Suurmeijer AJ, de Jong S, Jager PL, de Vries EG. Lub-de Hooge MN, et al. Among authors: de vries eg, de jong s. Br J Pharmacol. 2004 Sep;143(1):99-106. doi: 10.1038/sj.bjp.0705915. Epub 2004 Aug 2. Br J Pharmacol. 2004. PMID: 15289297 Free PMC article.

10

Testicular germ cell tumours: the paradigm of chemo-sensitive solid tumours.

di Pietro A, Vries EG, Gietema JA, Spierings DC, de Jong S. di Pietro A, et al. Among authors: de jong s. Int J Biochem Cell Biol. 2005 Dec;37(12):2437-56. doi: 10.1016/j.biocel.2005.06.014. Epub 2005 Aug 11. Int J Biochem Cell Biol. 2005. PMID: 16099193 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

850 results

Search Page

Filters